DNA Chip Based Prognosis of Lung Cancer

Conditions:		Carcinoma, Non-Small-Cell Lung
Purpose:		The purpose of the study is to determine whether a DNA chip, designed by Medical Prognosis Institute (MPI), can provide an accurate prognosis for survival of NSCLC (adeno-, squamous and large cell lung cancer).
Study Summary:
Criteria:		Inclusion Criteria: 1. A histological diagnosis of primary NSCLC stage Ia 2. Surgical removal of the tumor 3. Age between 18 and 75 years 4. Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: 1. A primary NSCLC stage Ia diagnosis that is changed to not primary NSCLC or NSCLC stage Ib-IV after surgery. 2. Adjuvant treatment with chemotherapy. 3. Prior history of cancer in the past 5 years or breast cancer at any time. 4. Life expectancy less than 3 years in the opinion of the investigator due to concurrent illnesses.
NCT ID:		NCT00973427
Primary Contact:		Study Chair Steen Knudsen, PhD Medical Prognosis Institute (MPI)
Backup Contact:		N/A
Location Contact:		Birmingham, Alabama 35294 United States Robert Cerfolio, MD Phone: 205-934-5937 Email: robert.cerfolio@ccc.uab.edu Site Status: Recruiting

Data Source:		ClinicalTrials.gov
Date Processed:		May 22, 2013
Modifications to this listing:		Only selected fields are shown, please use the link below to view all information about this clinical trial.
Click to view Full Listing


If you would like to be contacted by the clinical trial representative please enter your contact information, then click "I Am Interested In This Study"

First Name:

Last Name:

Email Address:

Confirm Email:

Daytime Phone (eg. 555-555-5555):

City:

State:

Zip Code:

Best Time to Call:

Morning	Afternoon	Evening
Please contact me by email instead of calling.

Questions/Comments:

I have read and agree with the Privacy Policy

I have reviewed the eligibility criteria and believe I am eligible for this clinical trial

I would like to be notified about new clinical trials.